News >

KTE-X19 MCL Application Enters EU Regulatory Pipeline

Gina Columbus
Published: Wednesday, Jan 29, 2020

Ken Takeshita, MD, global head of Clinical Development, Kite

Ken Takeshita, MD

The European Medicines Agency (EMA) has validated and is now evaluating a Marketing Authorization Application for the CAR T-cell therapy KTE-X19 for the treatment of adult patients with relapsed/refractory mantle cell lymphoma (MCL).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication